TREATMENT-RESISTANT DEPRESSION AND ANXIETY
|
|
|
- Brittney Horn
- 10 years ago
- Views:
Transcription
1 University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine
2 Definition of treatment resistance Failure to remit after 2 adequate trials of medication Includes remitters who relapse within a certain period of time
3 Determining treatment-resistance Wrong diagnosis Inadequate treatment Treatment intolerance True treatment resistance
4 Diagnostic issues Psychiatric Unipolar vs. bipolar depression Elevated rates of anxiety disorders in bipolar illness Medical Sleep apnea Thyroid dysfunction Substance Illicits Prescriptions: steroids, opioids, benzos
5 Treatment adequacy DOSE of Medication DURATION of Medication TYPE of Medication drug mechanism of action
6 Adequacy of antidepressant treatment SSRIs: Citalopram 20mg Escitalopram 10mg Fluoxetine 20mg Paroxetine 20mg Sertraline 100 mg SNRIs: Venlafaxine 150mg Bupropion 300mg Duloxetine 60mg Mirtazapine 30mg TCAs: Nortriptyline 75mg Amitriptyline 200mg Desipramine 200mg Minimal treatment duration: 4 weeks (Recommendations from D. Dunner)
7 Assuring appropriate type of medication Benzos do not work for PTSD TCAs do not work for social phobia Buspirone and Trazodone work ONLY for GAD Propranolol works only for performance anxiety Bupropion does not work for any anxiety disorder
8 Treatment intolerance and nonadherence Hypersensitivity to medications (especially in patients with high anxiety and panic) Negative beliefs about treatment efficacy (negative placebo response; more frequent treatment dropout) Recovery and acute illness model (late non-adherence) Fear of medication dependence (sometimes confused also with fears of medication addiction ) Prior adverse personal or familial experiences with medication Structural and other barriers to treatments low income, culture and ethnicity
9 Approaches to treatment intolerance Education and patient preparation (explanatory model, past experience, time course) Close monitoring for first few weeks Exposure with low dose, slow titration Side effects reframing consistent with patients own model of illness
10 Treatment resistance: key factors Exogenous factors Comorbidity Unimodal treatment
11 Treatment resistance: Exogenous factors Health Habits Caffeine Alcohol OTC cold preparations Nicotine (panic risk) Lack of exercise/ Deconditioning Sleep Deprivation Irregular sleep-wake cycle Life Events/Stress Acute Chronic (low SES; lack of social support) Substance Abuse Marijuana Cocaine Alcohol
12 Effect of psychosocial stressors on treatment response Disturbed spouse and family relationships predict lack of remission in GAD (Yonkers et al 2000) Chronic life stressors (interpersonal, danger, loss) diminish effect of anti-panic treatment (Wade et al, 1993) Poorer SSRI response in low income patients (Roy- Byrne et al, 2003) Poorer social support and more life events predict PTSD chronicity (Udwin et al, 2001)
13 Exercise is good for depression and anxiety Exercise is effective for mild to moderate depression (90 articles; Herring et al 2012) Exercise reduces cholecystokinin-induced panic (Stroehle et al 2005) Exercise is superior to placebo in reducing panic attacks and equal to medication in reducing anticipatory anxiety(brooks et al, 1998)
14 Treatment resistance: Comorbidity Major depression (especially recurrent, more severe) Anxiety disorders (especially various phobias) Personality Disorder Acute and long-term poor outcome predictor Substance Abuse Greatest effects on treatment engagement Alcohol also predicts poor outcome in engaged patients
15 Treatment resistance: Unimodal treatment Underutilization of evidence-based psychotherapy, such as CBT Non-MD therapists may delay medication until therapy has failed--now patient is biased against therapy
16 Treatment-resistance depression: Augmentation strategies Combining 2 antidepressants with complimentary mechanism of action or side effect profile eg., SSRI + bupropion, SSRI + TCA Atypical antipsychotics Use lower than antipsychotic dose, 6-8 week trial, discontinue if ineffective aripiprazole 10-15mg, olanzapine 5-10mg, risperidone 0.5-1mg, ziprasidone 60-80mg Lithium mg Liothyronine (Cytomel) mcg
17 Treatment-resistance depression: Other approaches ECT Usually quick response Needs maintenance medication to prevent relapse MAO Inhibitors phenelzine 60mg selegiline patch 6-12mg/24h tranylcypromine 40mg
18 Treatment-resistance anxiety: Pharmacotherapy Start with antidepressant baseline (SSRI, venlafaxine or mirtazapine) Wait long enough for complete response Adjunctive treatments Another antidepressant (esp. for panic disorder) Atypical antipsychotic for GAD or PTSD Anticonvulsant pregabalin for GAD and social phobia, lamotrigine for PTSD, gabapentin for social phobia Buspirone for social phobia Prazosin for nightmares and hyperarousal in PTSD Simplify regimen after 6 12 months
19 Treatment-resistance anxiety: Psychological treatment CBT Imagery rehearsal Mindfulness exercises
20 Did we mention exercise?
TREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
PTSD Evidence Based Practice Recommendations
PTSD Evidence ased Practice Recommendations Jason's ox est Practice Group Dr. Sam Moreno, Michelle Schnack Compilation & consolidation of the research and recommendations located in: The VA/DoD Clinical
NICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
Algorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
Treatment of Anxiety in the Methadone Maintained Patient
Treatment of Anxiety in the Methadone Maintained Patient Abigail Kay M.D., M.A. Medical Director Narcotic Addiction Rehabilitation Program Department of Psychiatry and Human Behavior Thomas Jefferson University
Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
Major Depression. What is major depression?
Major Depression What is major depression? Major depression is a serious medical illness affecting 9.9 million American adults, or approximately 5 percent of the adult population in a given year. Unlike
NICE clinical guideline 90
Depression in adults The treatment and management of depression in adults Issued: October 2009 NICE clinical guideline 90 guidance.nice.org.uk/cg90 NHS Evidence has accredited the process used by the Centre
Treatment of Patients With Major Depressive Disorder Second Edition
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder Second Edition WORK GROUP ON MAJOR DEPRESSIVE DISORDER T. Byram Karasu, M.D., Chair Alan Gelenberg, M.D. Arnold Merriam,
Antidepressant treatment in adults
Antidepressant treatment in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and
Bipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
Eating Disorder Treatment Protocol
Eating Disorder Treatment Protocol All Team Members: Patient Self-Management Education & Support Eating Disorders are incredibly debilitating and are associated with significant medical and psychosocial
Treatment and management of depression in adults, including adults with a chronic physical health problem
Issue date: October 2009 Depression Treatment and management of depression in adults, including adults with a chronic physical health problem This is an update of NICE clinical guideline 23 Developed by
Depression in adults with a chronic physical health problem
Depression in adults with a chronic physical health problem Treatment and management Issued: October 2009 NICE clinical guideline 91 guidance.nice.org.uk/cg91 NICE has accredited the process used by the
Medication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
Psychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
Recognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
Depression: management of depression in primary and secondary care
Issue date: December 2004 Quick reference guide Depression: management of depression in primary and secondary care Clinical Guideline 23 Developed by the National Collaborating Centre for Mental Health
Amendments to recommendations concerning venlafaxine
Amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised prescribing advice for venlafaxine*. This amendment brings the guideline into line with the new advice but does
Care Manager Resources: Common Questions & Answers about Treatments for Depression
Care Manager Resources: Common Questions & Answers about Treatments for Depression Questions about Medications 1. How do antidepressants work? Antidepressants help restore the correct balance of certain
Major Depressive Disorders Questions submitted for consideration by workshop participants
Major Depressive Disorders Questions submitted for consideration by workshop participants Prioritizing Comparative Effectiveness Research Questions: PCORI Stakeholder Workshops June 9, 2015 Patient-Centered
Depre r s e sio i n o i n i a dults Yousuf Al Farsi
Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis
Treatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
CLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
Anxiety Disorders Drug Treatment Guidelines
Western Australian Psychotropic Drugs Committee Anxiety Disorders Drug Treatment Guidelines August 2008 www.watag.org.au Table of Contents Executive Summary... 4 Psychological or pharmacological treatment?...
What are the best treatments?
What are the best treatments? Description of Condition Depression is a common medical condition with a lifetime prevalence in the United States of 15% among adults. Symptoms include feelings of sadness,
Depression in children and young people. Identification and management in primary, community and secondary care
NICE guideline May 2005 Issue date: September 2005 Depression in children and young people Identification and management in primary, community and secondary care Clinical Guideline 28 Developed by the
Treating Major Depressive Disorder
Treating Major Depressive Disorder A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition, originally published in October 2010.
Post-traumatic stress disorder overview
Post-traumatic stress disorder overview A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
Depression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
Depression Pathway. Patient Education Box 4. Guided self help Box 18. pg 11
LCFT localised Map pathway June 2009 Depression Pathway Instructions: Throughout this pathway if you click on the Bookmarks tab to the left of the screen and then click on the various documents you will
Recognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
IMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:
Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL
OVERVIEW OF COGNITIVE BEHAVIORAL THERAPY. 1 Overview of Cognitive Behavioral Therapy
OVERVIEW OF COGNITIVE BEHAVIORAL THERAPY 1 Overview of Cognitive Behavioral Therapy TABLE OF CONTENTS Introduction 3 What is Cognitive-Behavioral Therapy? 4 CBT is an Effective Therapy 7 Addictions Treated
Tension-type headache Non-pharmacological and pharmacological treatment
Danish Headache Center Tension-type headache Non-pharmacological and pharmacological treatment Lars Bendtsen Associate professor, MD, PhD, Dr Med Sci Danish Headache Center, Department of Neurology Glostrup
DEPRESSION IN PRIMARY CARE: An Overview. Jorge R. Petit, MD Quality Health Solutions
DEPRESSION IN PRIMARY CARE: An Overview Jorge R. Petit, MD Quality Health Solutions Topics In this Session Overview Clinical Importance of Depression Types of Depression Phases of Depression Care Collaborative
Assessment of depression in adults in primary care
Assessment of depression in adults in primary care Adapted from: Identification of Common Mental Disorders and Management of Depression in Primary care. New Zealand Guidelines Group 1 The questions and
Step 4: Complex and severe depression in adults
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
Topics in Addictions and Mental Health: Concurrent Disorders and Community Resources. Christian G. Schütz MD PhD MPH
Topics in Addictions and Mental Health: Concurrent Disorders and Community Resources Christian G. Schütz MD PhD MPH Overview Introduction Epidemiology Treatment Principles and Issues Community Resources
Why are antidepressants used to treat IBS? Some medicines can have more than one action (benefit) in treating medical problems.
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD What are functional GI disorders? There are more
1. Which of the following SSRIs requires up to a 5-week washout period because of the
1 Chapter 38. Major Depressive Disorders, Self-Assessment Questions 1. Which of the following SSRIs requires up to a 5-week washout period because of the long half-life of its potent active metabolite?
Generalised anxiety disorder in adults
www.bpac.org.nz keyword: anxiety Generalised anxiety disorder in adults diagnosis and management Key concepts: Anxiety disorders are the most frequently seen mental disorders in primary care Generalised
New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
Uncertainty: Was difficulty falling asleep and hypervigilance related to fear of ventricular tachycardia returning, or fear of being shocked again?
Manuel Tancer, MD Chart Review: PTSD PATIENT INFO 55 Age: Background: Overweight nurse with 6-month history of nightmares, hyperarousal, and flashbacks; symptoms began after implanted defibrillator was
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller School of Medicine/University of Miami Question 1 You
SESSION K2. When SSRIs Are Not Enough, What Then?
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 SESSION K2 3:55 When SSRIs Are Not Enough, What Then? Scott MacHaffie, MN, ARNP S E S S I O N Session Description:
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
Depression in children and young people. Quick reference guide. Issue date: September 2005
Quick reference guide Issue date: September 2005 Depression in children and young people Identification and management in primary, community and secondary care Clinical Guideline 28 Developed by the National
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
Antidepressants and suicidal thoughts and behaviour. Pharmacovigilance Working Party. January 2008
Antidepressants and suicidal thoughts and behaviour Pharmacovigilance Working Party January 2008 PhVWP PAR January 2008 Page 1/15 1. Introduction The Pharmacovigilance Working Party has on a number of
Adult Depression Clinical Practice Guideline
NATIONAL CLINICAL PRACTICE GUIDELINE Adult Depression Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent
Best Practices Treatment Guideline for Major Depression
Best Practices Treatment Guideline for Major Depression Special Report on New Depression Treatment Technology Based on 2010 APA Practice Guidelines Best Practices Guideline for the Treatment of Patients
Depression Treatment Guide
Depression Treatment Guide DSM V Criteria for Major Depressive Disorders A. Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous
Psychiatric Medications: Pearls and Pitfalls. The majority of medications used in patients with psychiatric diagnoses have more than one use.
Psychiatric Medications: Pearls and Pitfalls Rule #1 The majority of medications used in patients with psychiatric diagnoses have more than one use. Without access to the patient s medical record, to review
Overview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
TEXAS MEDICATION ALGORITHM PROJECT PROCEDURAL MANUAL
TEXAS MEDICATION ALGORITHM PROJECT PROCEDURAL MANUAL MAJOR DEPRESSIVE DISORDER ALGORITHMS Brandon Suehs, PharmD Tami R. Argo, PharmD, MS, BCPP Sherrie D. Bendele, BS M. Lynn Crismon, PharmD, BCPP Madhukar
Managing Chronic Pain in Adults with Substance Use Disorders
Question from chapter 1 Managing Chronic Pain in Adults with Substance Use Disorders 1) What is the percent of chronic pain patients who may have addictive disorders? a) 12% b) 22% c) 32% d) 42% 2) Which
DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
OCD & Anxiety: Helen Blair Simpson, M.D., Ph.D.
OCD & Anxiety: Symptoms, Treatment, & How to Cope Helen Blair Simpson, M.D., Ph.D. Professor of Clinical Psychiatry, Columbia University Director of the Anxiety Disorders Clinic, New York State Psychiatric
BENZODIAZEPINE CONSIDERATIONS IN WORKERS COMPENSATION: IMPLICATIONS FOR WORK DISABILITY AND CLAIM COSTS By: Michael Erdil MD, FACOEM
3 rd Quarter 2015 BENZODIAZEPINE CONSIDERATIONS IN WORKERS COMPENSATION: IMPLICATIONS FOR WORK DISABILITY AND CLAIM COSTS By: Michael Erdil MD, FACOEM Introduction Benzodiazepines, sometimes called "benzos",
Improving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
Medicines for Treating Depression. A Review of the Research for Adults
Medicines for Treating Depression A Review of the Research for Adults Is This Information Right for Me? Yes, if: A doctor or other health care professional has told you that you have depression. Your doctor
Sleep Medicine and Psychiatry. Roobal Sekhon, D.O.
Sleep Medicine and Psychiatry Roobal Sekhon, D.O. Common Diagnoses Mood Disorders: Depression Bipolar Disorder Anxiety Disorders PTSD and other traumatic disorders Schizophrenia Depression and Sleep: Overview
Depression. Medicines To Help You
Medicines To Help You Depression Use this guide to help you talk to your doctor, pharmacist, or nurse about your medicines for depression. The guide lists all of the FDA-approved products now available
POPULAR DEPRESSION MEDICATIONS
Popular Depression Medications A Helpful Guide to Antidepressant Drugs POPULAR DEPRESSION MEDICATIONS A Helpful Guide to Antidepressant Drugs Popular Depression Medications A Helpful Guide to Antidepressant
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Posttraumatic Stress Disorder
PERSPECTIVES The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Posttraumatic Stress Disorder Laura A. Bajor, DO, Ana Nectara Ticlea, MD, and David N. Osser, MD Background:
Brief Review of Common Mental Illnesses and Treatment
Brief Review of Common Mental Illnesses and Treatment Presentations to the Joint Subcommittee to Study Mental Health Services in the 21st Century September 9, 2014 Jack Barber, M.D. Medical Director Virginia
CLINICAL PRACTICE GUIDELINES. Depression
CLINICAL PRACTICE GUIDELINES Depression MOH Clinical Practice Guidelines 6/2011 3 1 Published by Ministry of Health, Singapore 16 College Road, College of Medicine Building Singapore 169854 Printed by
Professional Reference Series Depression and Anxiety, Volume 1. Depression and Anxiety Prevention for Older Adults
Professional Reference Series Depression and Anxiety, Volume 1 Depression and Anxiety Prevention for Older Adults TA C M I S S I O N The mission of the Older Americans Substance Abuse and Mental Health
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community
Identification, treatment and support for individuals with Alcohol & Drug Addiction in the Community Dr David Jackson Clinic Medical Officer The Hobart Clinic Association Drugs In tonight s context, drugs
Major Depressive Disorder: Evidence Based Practice
Major Depressive Disorder: Evidence Based Practice 1) For the diagnosis of MDD, the symptoms must be present for at least a) 2 weeks b) 4 weeks c) 90 days d) 2 months 2) If a MDD episode persists for over
How to Identify and Diagnose Depression
Depression Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Depression and MS Date of issue: March 2010 Review date: March 2011 Contents Introduction 2 1.
Child & Adolescent Anxiety: Psychopathology and Neuroscience
bbrfoundation.org Child & Adolescent Anxiety: Psychopathology and Neuroscience Daniel S. Pine, M.D. Chief, Child & Adolescent Research Mood & Anxiety Disorders Program National Institute of Mental Health
North Pacific Epilepsy Research 2311 NW Northrup Street Suite #202 Portland, Oregon 97210 Tel: 503-291-5300 Fax: 503-291-5303
North Pacific Epilepsy Research 2311 NW Northrup Street Suite #202 Portland, Oregon 97210 Tel: 503-291-5300 Fax: 503-291-5303 Post-Traumatic Stress Disorder (PTSD) Post-traumatic stress disorder (PTSD)
TITLE: Treatment for Post-Traumatic Stress Disorder, Operational Stress Injury, or Critical Incident Stress: A Review of Guidelines
TITLE: Treatment for Post-Traumatic Stress Disorder, Operational Stress Injury, or Critical Incident Stress: A Review of Guidelines DATE: 27 April 2015 CONTEXT AND POLICY ISSUES Critical incidents are
Evidence from years of increasing antidepressant use has
J. Sloan Manning What Alternatives to First-Line Therapy for Depression Are Effective? J. Sloan Manning, MD Depression is often a chronic illness that requires a methodical, long-term approach to manage